menu
    • menu
    [{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Naxitamab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swixx BioPharma \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Swixx BioPharma"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swixx BioPharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Amryt Pharma"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swixx BioPharma \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Swixx BioPharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Swixx BioPharma

    Menu

    Swixx BioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Swixx BioPharma

                            Switzerland arrow
                            Luxepack
                            Not Confirmed

                            Swixx BioPharma

                            Switzerland arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Eu...

                            Details : Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE. Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of HAE in adult and pediatric patients ...

                            Product Name : Orladeyo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Swixx BioPharma

                            Switzerland arrow
                            Luxepack
                            Not Confirmed

                            Swixx BioPharma

                            Switzerland arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naxitamab,Granulocyte-Macrophage Colony-Stimulating Factor

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® and Omburtamab in Eastern Europe

                            Details : Swixx BioPharma will exclusively distribute DANYELZA to treat patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including...

                            Product Name : Danyelza

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 18, 2020

                            Lead Product(s) : Naxitamab,Granulocyte-Macrophage Colony-Stimulating Factor

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Swixx BioPharma

                            Switzerland arrow
                            Luxepack
                            Not Confirmed

                            Swixx BioPharma

                            Switzerland arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Amryt Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Amryt and Swixx Sign Distribution Deal for Lojuxta

                            Details : Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.

                            Product Name : Lojuxta

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 19, 2020

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Amryt Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth